Evidence map›Paper›PMID 39132213›Full record

ArticleJournal of the Society for Cardiovascular Angiography & Interventions2024

Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y

Jennifer Rymer, Brooke Alhanti, Steven Kemp, Deepak L Bhatt, Ajar Kochar, Dominick J Angiolillo, Miguel Diaz, Kirk N Garratt, Neil J Wimmer, Ron Waksman and 13 more

Erratum issued Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04076813 (Cangrelor in Acute Myocardial Infarction), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04076813 active not recruitingnot on this map

Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

TypeobservationalSponsorChiesi USA, Inc.Ran2019 to 2025Enrolled5,050ConditionsMyocardial Infarction
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The role of cangrelor in acute and high-risk PCI settings.European heart journal. Cardiovascular pharmacotherapy · 2025
    Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Jennifer RymerDivision of Cardiology, Duke University School of Medicine, Durham, North Carolina.
Brooke AlhantiDuke Clinical Research Institute, Durham, North Carolina.
Steven KempDuke Clinical Research Institute, Durham, North Carolina.
Deepak L BhattMount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York.
Ajar KocharMount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York.
Dominick J AngiolilloDivision of Cardiovascular Medicine, University of Florida College of Medicine, Jacksonville, Florida.
Miguel DiazPalmetto General Hospital, Hialeah, Florida.
Kirk N GarrattChristianaCare, Newark, Delaware.
Neil J WimmerChristianaCare, Newark, Delaware.
Ron WaksmanWashington MedStar, Washington, District of Columbia.
Ajay J KirtaneNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Lawrence AngDivision of Cardiovascular Medicine, University of California San Diego, San Diego, California.
Richard BachCardiovascular Division, Washington University in St. Louis, St. Louis, Missouri.
Colin BarkerDivision of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee.
Ronald JenkinsKootenai Health, Coeur d'Alene, Idaho.
Mir B BasirHenry Ford Health, Detroit, Michigan.
Alex SullivanDivision of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee.
Hijrah El-SabaeChiesi USA Inc, Cary, North Carolina.
Leo BrothersDuke Clinical Research Institute, Durham, North Carolina.
E Magnus OhmanDuke Clinical Research Institute, Durham, North Carolina.
W Schuyler JonesDivision of Cardiology, Duke University School of Medicine, Durham, North Carolina.
Jeffrey B WashamDuke Clinical Research Institute, Durham, North Carolina.
Tracy Y WangDuke Clinical Research Institute, Durham, North Carolina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Little is known about the bleeding risk associated with cangrelor use in patients with myocardial infarction (MI) who are exposed to an oral P2Y Methods: Cangrelor in Acute MI: Effectiveness and Outcomes (CAMEO) is an observational registry studying platelet inhibition for patients with MI. Upstream oral P2Y Results: Among 1802 cangrelor-treated patients with MI, 385 (21.4%) received upstream oral P2Y Conclusions: Bleeding risk was not observed to be significantly higher after cangrelor treatment in patients with and without upstream oral P2Y12 inhibitor exposure.

Indexed as

bleedingcangrelormyocardial infarctionP2Y12 inhibitor

Identifiers

PMID39132213
PMCPMC11308101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.